- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 23
The Center for Biosimilars® recaps the top 5 articles for the week of April 23, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 23.
Number 5: A recent report demonstrates that there is unequal access to biologics and biosimilars for the treatment of inflammatory bowel disease among nations and regions worldwide.
Number 4: Australia’s Therapeutic Goods Administration has approved Celltrion’s rituximab biosimilar.
Number 3: The FDA’s Arthritis Advisory Committee recommended approval of only 1 of 2 proposed doses of baricitinib, a drug that many believed could compete for market share with Humira.
Number 2: A patient advocacy group is asking the Federal Trade Commission to investigate whether AbbVie’s recent settlements concerning patents on Humira violate the law.
Number 1: The Supreme Court of the United States ruled this week that the inter partes review process, which many biosimilar developers use to challenge patents on biologics, is constitutional.
Finally, last week, our e-newsletter asked whether you think that nurses are getting enough education about biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
